New kidney drug PMG1016 enters first human safety trial

NCT ID NCT07615985

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study tests a new drug called PMG1016 in 30 healthy adults to see if it is safe and how the body processes it. The drug is given as a single IV infusion. This is the first time PMG1016 is being tested in humans, and it aims to gather safety data before moving to patient studies for chronic kidney disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

PMG1016

What this could lead to

If safe, this could lead to a new treatment for chronic kidney disease, helping control the condition.

What could go wrong

This is a very early, small Phase 1 trial in healthy people, not patients. It only tests safety, not effectiveness. Many drugs fail at this stage.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Nucleus Network (Brisbane)

    Brisbane, Queensland, 4006, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••